潰瘍性大腸炎患者におけるトランスムラ療法は,内視鏡療法の単独治療と比較して長期的な結果を改善します
Chong-Teik Lim1,2, Christoph Teichert1, Maarten Pruijt1
1Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Journal of Crohn's & colitis
|August 22, 2025
まとめ
腸内超音波で評価された潰瘍性大腸炎 (UC) のトランスムラルヒーリング (TH) は,内視鏡治療 (EH) 単独よりも再発のリスクが低い. これは,IUSがUC患者の再発リスクを非侵襲的に予測するのに役立つことを示唆しています.
科学分野:
- 胃腸内科
- 炎症性腸疾患
- 医療用イメージング
背景:
- 内視鏡治療 (EH) は,潰瘍性大腸炎 (UC) の主要な治療目標です.
- 腸内超音波検査 (IUS) によって評価されたトランスムラルヒーリング (TH) は,さらなる予後的な洞察を提供することができます.
- この研究では,UC患者におけるTHとEH単独によるアウトカムを比較した.
研究 の 目的:
- 腸内超音波 (IUS) で評価されたUCにおけるトランスムラルヒーリング (TH) が患者の改善と相関するかどうかを調査する.
- THとTHのないUC患者のリクライプフリー生存を比較する.
- IUSをUCの治癒と再発を予測するツールとして評価する.
主な方法:
- 61人のUC患者の内視治癒 (EH; MES ≤1) の遡及的研究.
- 腸内超音波 (IUS) は,内視鏡検査の6ヶ月以内に実施され,THは腸壁の厚さ<3mmと定義される.
- 主要アウトカム: 再発のない生存率; 多変量コックス回帰が分析に使用された.
主要な成果:
- 患者の72%がIUSでTHを達成しました.
- 1年目の再発リスクは,TH患者 (29. 4%; p=0. 004) と比べ,TH患者 (7. 5%) で有意に低かった.
- 非TH (HR,3. 99) と女性の性別は再発と関連していたが,EHレベルはそうではなかった.
結論:
- UC患者におけるトランスムラルヒーリング (TH) は,内視鏡治療 (EH) 単独と比較して,再発のリスクの低下と関連しています.
- 腸内超音波 (IUS) は,UCの治癒を評価するための非侵襲的で費用対効果の高い方法を提供します.
- IUSはUC患者の再発リスクによる分層化に役立ちます.
関連する概念動画
01:21Inflammatory Bowel Disease V: Surgical Management
212
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
212
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
321
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
321
01:29Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
01:26Peptic Ulcer Disease IV: Management
145
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
145